Egon and Ann Diczfalusy Foundation
for
Supporting Research in Reproductive Health
In collaboration with the medical universities of Arad, Oradea, Timisoara (Romania), Novi Sad (Serbia) and Szeged (Hungary)
DICZFALUSY SYMPOSIUM ON REPRODUCTIVE HEALTH 14 November 2011, Szeged, Hungary
program V e n u e :
RESIDENCE OF THE HUNGARIAN ACADEMY OF SCIENCES 6720 Szeged, Somogyi u. 7.
Dear Friends and Colleagues, It is a great honour and a particular privilege for us to extend a most cordial welcome to the Fifth Meeting of the Egon and Ann Diczfalusy Foundation in Szeged. We are proud to present the Programme which is dedicated to Reproductive Health-care. This year the Conference has been incorporated as part of the prestigious Albert Szent-Györgyi Days of the University of Szeged. The Foundation, established in 2007 by the world famous reproductive endocrinologist professor Egon Diczfalusy and dedicated also to his late wife Ann, aims at disseminating knowledge and supporting scientific work conducted in the field of Reproductive Health. Each year it awards a Prize to a young investigator and a Medal to a senior scientist for his/ her life-time achievements. During the Conference several important topics will be discussed by well known international experts, ranging from oral progestins and venous thromboembolism, impact of obesity on Women’s Health, long-acting contraceptive agents and recent advance in perinatology. For the first time in the history of the Diczfalusy Award Lecture, a series of hands-on training will be held in the framework of parallel sessions about The risk of thromboembolism among obese patients, Application of Intrauterine device, Intrauterine System and Implants and Practical aspects of resuscitation and treatment of high risk neonates. We are confident that you will find your interest among the topics of the Conference and welcome you and wish all of you a most pleasant stay in Szeged, Hungary! The Presidium of the Foundation
Prof. György Bártfai President
Prof. Giuseppe Benagiano Prof. Márta Katona Prof. Henry L. Gabelnick Vice-President Vice-President Vice-President
The Diczfalusy prize
The Diczfalusy medal
Opening Session
0
09.00 – 09.10 Welcome and Opening Remarks. History of the Diczfalusy Foundation. 09.10 – 09.15 Laudatio of Biran Affandi, the recipient of the 2011 Diczfalusy Lecture Award. Laudator: David Archer 09.15 – 09.35 Acceptance Speech: Revitalization of Postpartum Contraceptive Use in Indonesia Speaker: Biran Affandi 09.35 – 09.40 Laudatio of Dunja Loncar, the recipient of the 2011 Young scientist award. Laudator: Signe Altmea 09.40 – 09.55 Acceptance Speeches: Dunja Loncar 09:55 – 10:00 Laudatio of Cristian-George Furau, the recipient of the 2011 Young scientist award. Laudator: Eszter Ducza 10:00 – 10:15 Acceptance Speeches: Cristian-George Furau First Session Oral progestins and venous thromboembolism Chair: Giuseppe Benaggiano, Gyula Telegdy
1
10:20 – 10:40 Biomarker research to understand haemostatic effects of combined oral contraceptives: do new estrogens carry a promise? 20’ Speaker: Kees Kluft 10:40 – 11:00 Drospirenon and VTE 20’ Speaker: Klaas Heinemann
3
11:00 – 11:20 Development of a low dose estrogen/progestin Transdermal Contraceptive System 20’ Speaker: David Archer 11:20 – 11:50
Discussion
11:50 – 13:00
LUNCHEON 70’
30’
Second Session The impact of obesity on Women’s Health Chair: David Archer, Tihomir Vejnovic
2
13:00 – 13:20 Failure of oral contraception in obese women: Role of altered pharmacokinetics of levonorgestrel 20’ Speaker: Ganesh Cherala 13:20 – 13:35 Practical aspects of obesity in contraception 15’ Speaker: Gábor Gimes 13:35 – 13:50 Obesity as a risk factor in Obstetric Care (from abortion to caesarian sections) 15’ Speaker: Boldizsár Horváth 13:50 – 14:05
Discussion 15’
Third Session Long-acting contraceptive agents Chair: Biran Affandi, György Thaler 14:05 – 14:25
Family planning guidelines and tools by WHO - Global Overview. Special emphasis on Contraceptive Implants 20’ Speaker: Moazzam Ali
14:25 – 14:45 Long Acting use of combined vaginal ring 20’ Speaker: Angelo Cagnacci
4
3
14:45 – 15:00 Intrauterine systems (IUS) and Intrauterine devices (IUD) 15’ Speaker: Tamás Major 15:00 – 15:15
Discussion 15’
15:15 – 15:35 COFFEE BREAK 20’ Fourth Session Meet the expert parallel sessions
4
1. Practical advice: The risk of thromboembolism among obese patients 15:35 – 16:20 Expert 1.: Gábor Gimes Expert 2.: Tamás Major 2. Practical aspects: Application of Intrauterine device, Intrauterine System and Implants 15:35 – 16:20 Expert 1.: Moazzam Ali Expert 2.: György Bártfai Fifth Session Recent advance in perinatology Chair: György Bártfai, Elena Bernad
5
16:20 – 16:40 Pre-term delivery, a European view 20’ Speaker: G iuseppe Benaggiano and Gian Carlo DiRenzo 16:40 – 17:00 Cerebral palsy: a critical overview 20’ Speaker: Anna Beke 17:00 – 17:20 Challenges in neonatal care (the very low birth weight infant) 20’ Speaker: György Balla
5
17:20 – 17:35 Discussion 15’ 17:35 – 17:40 Technical break 5’
Sixth Session Meet the expert parallel session
6
3. Practical aspects of implant application 17:40 – 18:25 Expert 1.: László Kalmár Expert 2.: Sándor Koloszár 4. Practical aspects of resuscitation and treatment of high risk neonates 17:40 – 18:25 Expert 1.: Márta Katona Expert 2.: Judit Kiss 18:25 – 18:40
Written test 15’
18:40 – 19:00 Presentation of the best poster awards and closing remarks 20’
Dinner
6
SPONSORS OF THE DICZFALUSY SYMPOSIUM ON REPRODUCTIVE HEALTH 14 November 2011, Szeged, Hungary
The Medical Faculty of the University of Szeged
7
Megbízhatóság és kényelem
• Hatékony hosszútávú fogamzásgátlás • Rövidebb és enyhébb vérzés • Szoptatás alatti alkalmazhatóság
Bayer Hungária Kft. 1123 Budapest, Alkotás u. 50. Tel.: 06-1-487-4100 Fax: 06-1-212-1574 www.baymedinfo.hu MIRENA® méhen belüli gyógyszerleadó rendszer (OGYI-T-6210/01) ATC: G03A03 H: 52 mg mikronizált levonorgesztrel. J: Fogamzásgátlás. Idiopathiás menorrhagia. Endometriális hyperplasia megelőzése ösztrogén-pótló terápia esetén. A: Az eszköz a méh üregébe helyezve 5 éven keresztül fejti ki hatását. A méh üregébe történő kezdeti levonorgesztrel felszabadulás mértéke 20µg/24h, 5 évre vetített átl. értéke 14µg/24h. E: Terhesség v. annak gyanúja; kismedencei gyulladásos folyamatok; alsó genitális infekció; postpartum endometritis; fertőzéses szövődménnyel járó vetélés 3 hónapon belül; cervicitis; méhnyaki dysplasia; uterus- v. cervix-tumor; progeszteron-függő tumorok; tisztázatlan eredetű méhvérzés; uterus veleszületett v. szerzett alaki rendellenességei; fertőzésekkel szembeni fokozott érzékenységgel járó állapot; akut májbetegség v. májtumor; gy.érz.. M: depresszió, idegesség, fejfájás, hasi fájdalom, hányinger, akne, hátfájás, medencei fájdalom, vaginális folyás, vulvovaginitis, mellérz, mell fájdalom, eszköz kilöködés, súlygyarapodás. Kiadhatóság: Orvosi rendelvényhez kötött gyógyszer (Sz). Kérjük olvassa el a gyógyszer alkalmazási előiratát! A rövidített leírás forrásául szolgáló, hivatalos alkalmazási leírás dátuma: 2011.09.21.
L.PH.WH.Mirena.2011-11-09.2164
• Elégedett páciensek
